Summary & Overview
HCPCS Level II S0176: Hydroxyurea, Oral, 500 mg
HCPCS Level II code S0176 designates oral hydroxyurea 500 mg, an antineoplastic agent commonly used in hematologic conditions and certain malignancies. Nationally, accurate coding for oral chemotherapy agents matters for pharmacy billing, benefit design, patient cost-sharing, and claims adjudication. HCPCS Level II codes like S0176 enable consistent identification of dispensed oncology medications on claims and facilitate coordination between medical and pharmacy benefits.
This analysis covers major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing context for oral chemotherapy, payer coverage considerations, typical sites of service, and the practical implications for claim documentation. The content includes benchmark-oriented information on how the code is used across payer types, policy and coverage update summaries where available, and clinical context for hydroxyurea dosing form and administration setting.
The report does not provide clinical recommendations. It offers concise reference material for billing staff, revenue cycle managers, and policy analysts seeking a national-level summary of HCPCS Level II code S0176 and its role in outpatient and pharmacy-related oncology billing.
Billing Code Overview
HCPCS Level II code S0176 represents Hydroxyurea, oral, 500 mg. This code denotes a prescription oral chemotherapy agent formulation at a 500 mg unit strength.
Service Type: Oral chemotherapy / antineoplastic agent
Typical Site of Service: Outpatient clinic, specialty pharmacy dispensing, or patient self-administered at home
Clinical & Coding Specifications
Clinical Context
A typical outpatient hematology-oncology patient with sickle cell disease receives chronic oral hydroxyurea therapy to reduce vaso-occlusive episodes and acute chest syndrome. A 28-year-old patient presents to a specialty infusion clinic or ambulatory pharmacy for medication refill and monthly monitoring. The clinical workflow includes prescription verification, medication dispensing of S0176 (Hydroxyurea, oral, 500 mg), counseling on adherence and adverse effects, and ordering laboratory monitoring (CBC with differential, reticulocyte count, renal and liver function tests) prior to dose continuation or adjustment. Documentation captures diagnosis, current dose, quantity dispensed, lot number, and laboratory results; billing uses the S0176 HCPCS Level II code for the dispensed unit, with appropriate modifier if applicable (for example, a modifier for unusual services or for split/shared services in certain payor requirements). Typical sites of service are outpatient specialty clinics, ambulatory infusion centers with pharmacy services, and outpatient hospital pharmacies. The patient scenario commonly includes chronic follow-up visits every 1–3 months with periodic dose titration based on hematologic response and toxicity monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no specific modifier applies |
22 | Increased procedural services | Use when additional work or resources were required related to medication counseling or complex medication management |
23 | Unusual anesthesia | Not typically applicable to oral medication dispensing; listed for completeness |
52 | Reduced services | Use when a portion of the expected pharmacy or clinical service was not provided |
53 | Discontinued procedure | Use when therapy was initiated but discontinued before completion of planned dispensing process |
62 | Two surgeons | Not typically applicable to pharmacy dispensing; applicable if two qualified clinicians shared responsibility |
78 | Return to operating room | Not applicable to routine oral medication dispensing |
80 | Assistant surgeon | Not typically applicable to medication dispensing |
82 | Assistant surgeon (when qualified assistant not available) | Not typically applicable to medication dispensing |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist | Use when service is performed by an advanced practice provider |
CO | Cast/other orthotic | Not applicable to medication dispensing |
CQ | Service furnished by a pharmacy under a collaborative practice agreement | Use when the dispensing and medication management occur under a pharmacist collaborative practice agreement |
QK | Medical direction of two, three, or four concurrent anesthesia procedures | Not applicable to medication dispensing |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RH0000X | Hematology & Oncology | Specialist managing sickle cell disease and hydroxyurea therapy |
3336P0800X | Clinical Pharmacy Specialist | Pharmacist providing medication management and monitoring under collaborative practice |
363L00000X | Nurse Practitioner | Advanced practice provider frequently managing chronic hydroxyurea therapy |
207K00000X | Medical Oncology | Oncology specialist who may prescribe hydroxyurea for hematologic indications |
208M00000X | Pediatric Hematology-Oncology | Specialist caring for pediatric patients on hydroxyurea |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
D57.0 | Sickle-cell anemia with crisis | Primary indication for chronic hydroxyurea to reduce vaso-occlusive crises |
D57.1 | Sickle-cell disease without crisis | Indication for hydroxyurea to reduce disease complications and acute events |
D57.2 | Double heterozygous sickling disorders | Hydroxyurea used for management of hemoglobinopathy variants |
D63.1 | Anemia in chronic disorders | Supportive diagnosis when hydroxyurea therapy impacts hematologic indices |
Z79.01 | Long term (current) use of anticoagulants | Example of a long-term medication code format; note for medication reconciliation (not a direct indication) |
Z51.11 | Encounter for antineoplastic chemotherapy | Used when hydroxyurea is part of ongoing cytoreductive therapy visits |
R79.89 | Other specified abnormal findings of blood chemistry | May appear in monitoring contexts when lab abnormalities prompt medication adjustment |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
81025 | Urine pregnancy test, by visual color comparison methods | Performed prior to initiation or during therapy in women of childbearing potential |
85025 | Complete blood count (CBC) with automated differential | Routine laboratory monitoring to assess marrow suppression and therapy response |
80053 | Comprehensive metabolic panel | Monitoring renal and hepatic function during hydroxyurea therapy |
36415 | Collection of venous blood by venipuncture | Standard specimen collection for labs required before continuing or adjusting therapy |
99213 | Office or other outpatient visit for the evaluation and management of an established patient, low to moderate complexity | Typical follow-up visit for medication management, dose adjustment, and counseling |